Although HCV infection is highly prevalent in East Asia, these patients have been underrepresented in HRQL studies. Here, we assess HRQL in East Asian HCV pa- 
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Summary
Although HCV infection is highly prevalent in East Asia, these patients have been China. 3 In addition to causing liver-related complications, HCV is also responsible for a number of potentially disabling extrahepatic manifestations such as chronic fatigue, depression, mixed cryoglobulinemia and lymphoma. [4] [5] [6] In turn, both hepatic and extrahepatic manifestations of HCV have been linked to impairment of healthrelated quality of life (HRQL) in chronically infected patients.
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Furthermore, HCV is responsible for substantial resource utilization worldwide which includes both direct and indirect costs associated with the infection. 7, [12] [13] [14] [15] In this context, only systematic assessment of clinical outcomes, patient-reported outcomes such as HRQL and economic outcomes would allow estimating the comprehensive burden of HCV infection.
7,16
Until recently, treatment of HCV in East Asian countries has largely been limited to interferon (IFN)-based regimens with relatively good efficacy but significant side effects. [17] [18] [19] [20] [21] However, over the last 5 years, treatment of HCV has been revolutionized with the new IFN-free regimens which are based on direct-acting antiviral agents (DAAs) with excellent efficacy and tolerability profiles. [19] [20] [21] [22] [23] [24] Despite their obvious superiority, DAAs for treatment of HCV are still not universally available in East Asian countries.
17,18
In a recent clinical trial, one of the interferon-and ribavirin-free DAA-based regimens containing sofosbuvir (SOF) and ledipasvir (LDV) demonstrated excellent efficacy and safety profile in East Asian patients. 25 To complement this for the purpose of appreciating the comprehensive benefit of this treatment regimen, we aimed to report HRQL outcomes of HCV-infected patients enrolled in East
Asian countries and to compare them to the outcomes of patients treated with interferon-and/or ribavirin-containing regimens from the same region of the world.
| ME THODS
The data were collected as a part of a multinational phase 3 clinical trial (GS-US-337-0131, clinicaltrials.gov # NCT02021656) which was conducted in East Asia (China, Taiwan, South Korea) in 2013-2017. 26 We also calculated SF-6D health utility scores using the items of the SF-36 and a nonparametric Bayesian algorithm. 
| Statistical analysis
Health-related quality of life data accompanied by similarly collected demographic and clinical data from historic controls included in our HRQL registry were used for comparison. All analyses were run in SAS 9.4 (SAS Institute, Cary, NC, USA).
All patients signed an informed consent, and the study was approved by each site's Institutional Review Board.
| RE SULTS
There were 384 patients enrolled in the trial of LDV/SOF. From our HRQL registry, we also extracted historic data for 605 controls with chronic HCV infection who had been enrolled from the same countries; 130 had been treated with Peg-IFN + RBV + SOF, and 475 with SOF + RBV ( 
| Safety and efficacy
As expected, patients treated with IFN-free RBV-free LDV/SOF had the lowest rates of nearly all studied adverse events (all P < 0.001). In fact, in 85.7% of patients receiving LDV/SOF, no treatment-related adverse events were reported, compared to 51.4% in patients treated with SOF + RBV, and 8.5% in the Peg-IFN + RBV + SOF-treated group (Table 2 ). In addition, the rate of 
| Health-related quality of life
Baseline HRQL scores of the study cohort are shown in Table 3 by the treatment regimen, Table S1 by the country of enrolment. There was moderate variation in baseline scores between the treatment regimen groups (all P ≥ 0.01) and also between patients from different countries (P < 0.05 for 6 of 8 studied HRQL domains, MCS and SF-6D) along with notable variability in demographics.
Independent predictors of baseline HRQL scores are summarized in Table S2 . Factors most consistently associated with lower HRQL Table 3 ). In addition, patients treated with SOF + RBV had significant declines in PF, RP, BP, SF, RE, PCS, MCS and SF-6D (on average, −2.8 to −5.8 points, with the greatest in RP and RE; P < 0.05) ( Figure 1 , Table 3 ). In contrast, patients treated with LDV/SOF experienced no HRQL declines and had improvements in GH, VT, MH, MCS and SF-6D (on average, +4.1 to +4.3 points; P < 0.05) ( Figure 1 , Table 3 ).
In post-treatment follow-up, HRQL scores of patients who Table 3 ). In addition, improvements in GH, VT, MH and MCS were significant in the SOF + RBV group only (+2.0 to +2.8 points, P < 0.05). At the same time, all HRQL improvements became more prominent in the LDV/SOF group (up to +5.7 points in VT, P < 0.05 for PF, GH, VT, RE, MH, PCS, MCS, SF-6D) ( Figure 1 , Table 3 ).
In multivariate regression analysis, after adjustment for demo- Table S3 ). 
LDV/SOF (n = 384)
| Subgroup analysis: patients enrolled in China
Similar analysis of HRQL changes was run using a subgroup of pa- 
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